The global market for Castration-resistant Prostate Cancer Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Castration-resistant Prostate Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-resistant Prostate Cancer Drugs.

The Castration-resistant Prostate Cancer Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Castration-resistant Prostate Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Castration-resistant Prostate Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Castration-resistant Prostate Cancer Drugs Market Report

Report Metric	Details
Report Name	Castration-resistant Prostate Cancer Drugs Market
CAGR	5%
Segment by Type	Oral Intravenous Injection Others
Segment by Application	Hospital Specialty Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Astellas, Janssen, AstraZeneca, Bayer, Hengrui, CTTQ, Sanofi, Hansoh, Clovis Oncology, Zhendong Pharmaceutical, Merck
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Castration-resistant Prostate Cancer Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Castration-resistant Prostate Cancer Drugs Market report?

Ans: The main players in the Castration-resistant Prostate Cancer Drugs Market are Pfizer, Astellas, Janssen, AstraZeneca, Bayer, Hengrui, CTTQ, Sanofi, Hansoh, Clovis Oncology, Zhendong Pharmaceutical, Merck

What are the Application segmentation covered in the Castration-resistant Prostate Cancer Drugs Market report?

Ans: The Applications covered in the Castration-resistant Prostate Cancer Drugs Market report are Hospital, Specialty Clinic, Others

What are the Type segmentation covered in the Castration-resistant Prostate Cancer Drugs Market report?

Ans: The Types covered in the Castration-resistant Prostate Cancer Drugs Market report are Oral, Intravenous Injection, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Oral

1.2.3 Intravenous Injection

1.2.4 Others

1.3 Market by Application

1.3.1 Global Castration-resistant Prostate Cancer Drugs Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Specialty Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Castration-resistant Prostate Cancer Drugs Market Perspective (2020-2031)

2.2 Global Castration-resistant Prostate Cancer Drugs Growth Trends by Region

2.2.1 Global Castration-resistant Prostate Cancer Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Castration-resistant Prostate Cancer Drugs Historic Market Size by Region (2020-2025)

2.2.3 Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Region (2026-2031)

2.3 Castration-resistant Prostate Cancer Drugs Market Dynamics

2.3.1 Castration-resistant Prostate Cancer Drugs Industry Trends

2.3.2 Castration-resistant Prostate Cancer Drugs Market Drivers

2.3.3 Castration-resistant Prostate Cancer Drugs Market Challenges

2.3.4 Castration-resistant Prostate Cancer Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Castration-resistant Prostate Cancer Drugs Players by Revenue

3.1.1 Global Top Castration-resistant Prostate Cancer Drugs Players by Revenue (2020-2025)

3.1.2 Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Players (2020-2025)

3.2 Global Castration-resistant Prostate Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Castration-resistant Prostate Cancer Drugs Revenue

3.4 Global Castration-resistant Prostate Cancer Drugs Market Concentration Ratio

3.4.1 Global Castration-resistant Prostate Cancer Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Castration-resistant Prostate Cancer Drugs Revenue in 2024

3.5 Global Key Players of Castration-resistant Prostate Cancer Drugs Head office and Area Served

3.6 Global Key Players of Castration-resistant Prostate Cancer Drugs, Product and Application

3.7 Global Key Players of Castration-resistant Prostate Cancer Drugs, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Castration-resistant Prostate Cancer Drugs Breakdown Data by Type

4.1 Global Castration-resistant Prostate Cancer Drugs Historic Market Size by Type (2020-2025)

4.2 Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Type (2026-2031)

5 Castration-resistant Prostate Cancer Drugs Breakdown Data by Application

5.1 Global Castration-resistant Prostate Cancer Drugs Historic Market Size by Application (2020-2025)

5.2 Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Castration-resistant Prostate Cancer Drugs Market Size (2020-2031)

6.2 North America Castration-resistant Prostate Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Castration-resistant Prostate Cancer Drugs Market Size by Country (2020-2025)

6.4 North America Castration-resistant Prostate Cancer Drugs Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Castration-resistant Prostate Cancer Drugs Market Size (2020-2031)

7.2 Europe Castration-resistant Prostate Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Castration-resistant Prostate Cancer Drugs Market Size by Country (2020-2025)

7.4 Europe Castration-resistant Prostate Cancer Drugs Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size (2020-2031)

8.2 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region (2020-2025)

8.4 Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Castration-resistant Prostate Cancer Drugs Market Size (2020-2031)

9.2 Latin America Castration-resistant Prostate Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Castration-resistant Prostate Cancer Drugs Market Size by Country (2020-2025)

9.4 Latin America Castration-resistant Prostate Cancer Drugs Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size (2020-2031)

10.2 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country (2020-2025)

10.4 Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Details

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Castration-resistant Prostate Cancer Drugs Introduction

11.1.4 Pfizer Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.1.5 Pfizer Recent Development

11.2 Astellas

11.2.1 Astellas Company Details

11.2.2 Astellas Business Overview

11.2.3 Astellas Castration-resistant Prostate Cancer Drugs Introduction

11.2.4 Astellas Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.2.5 Astellas Recent Development

11.3 Janssen

11.3.1 Janssen Company Details

11.3.2 Janssen Business Overview

11.3.3 Janssen Castration-resistant Prostate Cancer Drugs Introduction

11.3.4 Janssen Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.3.5 Janssen Recent Development

11.4 AstraZeneca

11.4.1 AstraZeneca Company Details

11.4.2 AstraZeneca Business Overview

11.4.3 AstraZeneca Castration-resistant Prostate Cancer Drugs Introduction

11.4.4 AstraZeneca Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.4.5 AstraZeneca Recent Development

11.5 Bayer

11.5.1 Bayer Company Details

11.5.2 Bayer Business Overview

11.5.3 Bayer Castration-resistant Prostate Cancer Drugs Introduction

11.5.4 Bayer Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.5.5 Bayer Recent Development

11.6 Hengrui

11.6.1 Hengrui Company Details

11.6.2 Hengrui Business Overview

11.6.3 Hengrui Castration-resistant Prostate Cancer Drugs Introduction

11.6.4 Hengrui Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.6.5 Hengrui Recent Development

11.7 CTTQ

11.7.1 CTTQ Company Details

11.7.2 CTTQ Business Overview

11.7.3 CTTQ Castration-resistant Prostate Cancer Drugs Introduction

11.7.4 CTTQ Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.7.5 CTTQ Recent Development

11.8 Sanofi

11.8.1 Sanofi Company Details

11.8.2 Sanofi Business Overview

11.8.3 Sanofi Castration-resistant Prostate Cancer Drugs Introduction

11.8.4 Sanofi Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.8.5 Sanofi Recent Development

11.9 Hansoh

11.9.1 Hansoh Company Details

11.9.2 Hansoh Business Overview

11.9.3 Hansoh Castration-resistant Prostate Cancer Drugs Introduction

11.9.4 Hansoh Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.9.5 Hansoh Recent Development

11.10 Clovis Oncology

11.10.1 Clovis Oncology Company Details

11.10.2 Clovis Oncology Business Overview

11.10.3 Clovis Oncology Castration-resistant Prostate Cancer Drugs Introduction

11.10.4 Clovis Oncology Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.10.5 Clovis Oncology Recent Development

11.11 Zhendong Pharmaceutical

11.11.1 Zhendong Pharmaceutical Company Details

11.11.2 Zhendong Pharmaceutical Business Overview

11.11.3 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Introduction

11.11.4 Zhendong Pharmaceutical Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.11.5 Zhendong Pharmaceutical Recent Development

11.12 Merck

11.12.1 Merck Company Details

11.12.2 Merck Business Overview

11.12.3 Merck Castration-resistant Prostate Cancer Drugs Introduction

11.12.4 Merck Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

11.12.5 Merck Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Zhendong Pharmaceutical

Merck

List of Tables

Table 1. Global Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Oral

Table 3. Key Players of Intravenous Injection

Table 4. Key Players of Others

Table 5. Global Castration-resistant Prostate Cancer Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Castration-resistant Prostate Cancer Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Castration-resistant Prostate Cancer Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Castration-resistant Prostate Cancer Drugs Market Share by Region (2020-2025)

Table 9. Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Castration-resistant Prostate Cancer Drugs Market Share by Region (2026-2031)

Table 11. Castration-resistant Prostate Cancer Drugs Market Trends

Table 12. Castration-resistant Prostate Cancer Drugs Market Drivers

Table 13. Castration-resistant Prostate Cancer Drugs Market Challenges

Table 14. Castration-resistant Prostate Cancer Drugs Market Restraints

Table 15. Global Castration-resistant Prostate Cancer Drugs Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Castration-resistant Prostate Cancer Drugs Market Share by Players (2020-2025)

Table 17. Global Top Castration-resistant Prostate Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-resistant Prostate Cancer Drugs as of 2024)

Table 18. Ranking of Global Top Castration-resistant Prostate Cancer Drugs Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Castration-resistant Prostate Cancer Drugs Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Castration-resistant Prostate Cancer Drugs, Headquarters and Area Served

Table 21. Global Key Players of Castration-resistant Prostate Cancer Drugs, Product and Application

Table 22. Global Key Players of Castration-resistant Prostate Cancer Drugs, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Castration-resistant Prostate Cancer Drugs Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Type (2020-2025)

Table 26. Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Type (2026-2031)

Table 28. Global Castration-resistant Prostate Cancer Drugs Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Application (2020-2025)

Table 30. Global Castration-resistant Prostate Cancer Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Castration-resistant Prostate Cancer Drugs Revenue Market Share by Application (2026-2031)

Table 32. North America Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Castration-resistant Prostate Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Castration-resistant Prostate Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Castration-resistant Prostate Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Castration-resistant Prostate Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Castration-resistant Prostate Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Castration-resistant Prostate Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size by Country (2026-2031) & (US$ Million)

Table 47. Pfizer Company Details

Table 48. Pfizer Business Overview

Table 49. Pfizer Castration-resistant Prostate Cancer Drugs Product

Table 50. Pfizer Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 51. Pfizer Recent Development

Table 52. Astellas Company Details

Table 53. Astellas Business Overview

Table 54. Astellas Castration-resistant Prostate Cancer Drugs Product

Table 55. Astellas Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 56. Astellas Recent Development

Table 57. Janssen Company Details

Table 58. Janssen Business Overview

Table 59. Janssen Castration-resistant Prostate Cancer Drugs Product

Table 60. Janssen Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 61. Janssen Recent Development

Table 62. AstraZeneca Company Details

Table 63. AstraZeneca Business Overview

Table 64. AstraZeneca Castration-resistant Prostate Cancer Drugs Product

Table 65. AstraZeneca Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 66. AstraZeneca Recent Development

Table 67. Bayer Company Details

Table 68. Bayer Business Overview

Table 69. Bayer Castration-resistant Prostate Cancer Drugs Product

Table 70. Bayer Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 71. Bayer Recent Development

Table 72. Hengrui Company Details

Table 73. Hengrui Business Overview

Table 74. Hengrui Castration-resistant Prostate Cancer Drugs Product

Table 75. Hengrui Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 76. Hengrui Recent Development

Table 77. CTTQ Company Details

Table 78. CTTQ Business Overview

Table 79. CTTQ Castration-resistant Prostate Cancer Drugs Product

Table 80. CTTQ Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 81. CTTQ Recent Development

Table 82. Sanofi Company Details

Table 83. Sanofi Business Overview

Table 84. Sanofi Castration-resistant Prostate Cancer Drugs Product

Table 85. Sanofi Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 86. Sanofi Recent Development

Table 87. Hansoh Company Details

Table 88. Hansoh Business Overview

Table 89. Hansoh Castration-resistant Prostate Cancer Drugs Product

Table 90. Hansoh Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 91. Hansoh Recent Development

Table 92. Clovis Oncology Company Details

Table 93. Clovis Oncology Business Overview

Table 94. Clovis Oncology Castration-resistant Prostate Cancer Drugs Product

Table 95. Clovis Oncology Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 96. Clovis Oncology Recent Development

Table 97. Zhendong Pharmaceutical Company Details

Table 98. Zhendong Pharmaceutical Business Overview

Table 99. Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Product

Table 100. Zhendong Pharmaceutical Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 101. Zhendong Pharmaceutical Recent Development

Table 102. Merck Company Details

Table 103. Merck Business Overview

Table 104. Merck Castration-resistant Prostate Cancer Drugs Product

Table 105. Merck Revenue in Castration-resistant Prostate Cancer Drugs Business (2020-2025) & (US$ Million)

Table 106. Merck Recent Development

Table 107. Research Programs/Design for This Report

Table 108. Key Data Information from Secondary Sources

Table 109. Key Data Information from Primary Sources

Table 110. Authors List of This Report

List of Figures

Figure 1. Castration-resistant Prostate Cancer Drugs Picture

Figure 2. Global Castration-resistant Prostate Cancer Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Castration-resistant Prostate Cancer Drugs Market Share by Type: 2024 VS 2031

Figure 4. Oral Features

Figure 5. Intravenous Injection Features

Figure 6. Others Features

Figure 7. Global Castration-resistant Prostate Cancer Drugs Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Castration-resistant Prostate Cancer Drugs Market Share by Application: 2024 VS 2031

Figure 9. Hospital Case Studies

Figure 10. Specialty Clinic Case Studies

Figure 11. Others Case Studies

Figure 12. Castration-resistant Prostate Cancer Drugs Report Years Considered

Figure 13. Global Castration-resistant Prostate Cancer Drugs Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 14. Global Castration-resistant Prostate Cancer Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 15. Global Castration-resistant Prostate Cancer Drugs Market Share by Region: 2024 VS 2031

Figure 16. Global Castration-resistant Prostate Cancer Drugs Market Share by Players in 2024

Figure 17. Global Top Castration-resistant Prostate Cancer Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Castration-resistant Prostate Cancer Drugs as of 2024)

Figure 18. The Top 10 and 5 Players Market Share by Castration-resistant Prostate Cancer Drugs Revenue in 2024

Figure 19. North America Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 20. North America Castration-resistant Prostate Cancer Drugs Market Share by Country (2020-2031)

Figure 21. United States Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Canada Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Castration-resistant Prostate Cancer Drugs Market Share by Country (2020-2031)

Figure 25. Germany Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. France Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. U.K. Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Italy Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Russia Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Nordic Countries Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Castration-resistant Prostate Cancer Drugs Market Share by Region (2020-2031)

Figure 33. China Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Japan Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. South Korea Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Southeast Asia Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. India Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Australia Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Castration-resistant Prostate Cancer Drugs Market Share by Country (2020-2031)

Figure 41. Mexico Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Brazil Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Castration-resistant Prostate Cancer Drugs Market Share by Country (2020-2031)

Figure 45. Turkey Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Saudi Arabia Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. UAE Castration-resistant Prostate Cancer Drugs Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Pfizer Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 49. Astellas Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 50. Janssen Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 51. AstraZeneca Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 52. Bayer Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 53. Hengrui Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 54. CTTQ Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 55. Sanofi Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 56. Hansoh Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 57. Clovis Oncology Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 58. Zhendong Pharmaceutical Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 59. Merck Revenue Growth Rate in Castration-resistant Prostate Cancer Drugs Business (2020-2025)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Prostate Cancer Diagnostics and Therapy Market Research Report 2024

Global Prostate Cancer Diagnosis and Therapy Market Research Report 2024

Prostate Cancer Treatment Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Prostate Cancer Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Testicular Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Small Molecule Cancer Drug Market Research Report 2025

Global Gynecological Cancers Drug Market Research Report 2025

Global Kidney Cancer Diagnosis Market Research Report 2025

Hair Loss Treatment for Man Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Solid Tumor Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Oncology Anti cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Radiotherapy Device Market Research Report 2024

Global Targeted Drugs for Breast Cancer Market Research Report 2024

Global Advanced Prostate Cancer Drug Market Research Report 2025

Global Hair Loss Growth Treatment Market Research Report 2025

Global Oncolytic Virus Drug Treatment Market Research Report 2025

Novel Drug Delivery Systems for Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Personalized Medicine for Cancer Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions